INTRODUCTION
Although epidermal growth factor (EGF) and thyroidstimulating hormone (TSH) both stimulate thyroid growth, their effects on thyroid function are antagonistic [1, 2] . EGF inhibits thyroid iodide uptake, prothyroid hormone synthesis, thyroperoxidase synthesis and iodide organification, all of which are required for thyroid hormone synthesis [3] . The signalling events mediated by these ligands in fully differentiated thyroid cells, and the interactions between the signalling pathways, remain ill-defined. The TSH receptor is coupled to adenylate cyclase activation and many of the effects of TSH on thyroid function are mimicked by forskolin and dibutyryl cyclic AMP (dbcAMP). However, transfection of the cloned human TSH receptor into Chinese hamster ovary cells has shown that the receptor can also be coupled to second messengers generated following inositol lipid hydrolysis [4] . This coupling is presumably through Gq and phospholipase C,# (PLC,I) activation. Whether TSH activates this pathway in thyroid cells from all species is a matter of controversy which may be resolved by the findings of regulation of TSH receptor signalling by purinergic receptors. Adenosine has been shown to sensitize the TSH-coupled PLC pathway in FRTL5 cells [5] , a rat thyroid-derived cell line which shows some differentiated thyroid function. In this cell line, antibodies to the TSH receptor have been shown to activate phospholipase A2 (PLA2) [6] and, consistent with this, many earlier studies have shown TSH-induced increases in arachidonate and prostaglandins [7] [8] [9] [10] [11] . The actions of TSH in stimulating thyroid cell growth and differentiation require the presence of insulin or insulin-like growth factor 1 (IGF-1) [12] [13] [14] , implying that cooperation is required with a second signalling pathway. Thus TSH clearly utilizes a range of signalling mechanisms.
after treatment of sheep thyrocytes with EGF for 24 h. This is consistent with maintenance of the intracellular concentration of myo-inositol as the cells enlarge in preparation for cell division. In TSH-treated cells, however, up-regulation of myo-inositol transport was linked with increased myo-inositol cycling across the cell membrane, increased phospholipase A2-mediated turnover of phosphatidylinositol and a concomitant increase in arachidonic acid turnover. Increased levels of myo-inositol phosphates were also noted 24 h after TSH treatment. These results indicate the initiation of secondary signalling events many hours after the primary stimulus.
A similar conclusion can be made with regard to EGF-induced signalling. The EGF receptor has intrinsic tyrosine kinase activity which is revealed upon EGF binding. This receptor has recently been shown to activate PLCyl through phosphorylation of its SH2 domain [15] . Consistent with activation of this pathway, which would result in protein kinase C (PKC) activation, the phorbol ester phorbol 12-myristate 13-acetate can mimic many of the EGF effects in the thyroid and elsewhere [16] . EGF can inhibit many aspects of TSH-induced thyroid cell differentiation in functional primary cell cultures [1, 2, 17, 18] . In v-ras-transformed FRTL5 cells, activation of PKC inhibited the migration of the catalytic subunit of protein kinase A (PKA) to the nucleus, illustrating the possible basis for interactions between the signalling pathways [19] . At the cell membrane, however, there is no evidence for interference by EGF in the response of thyroid cells to acute challenge with TSH in cyclic AMP assays, although accumulated levels of cyclic AMP were reduced in EGF plus TSH-treated cells [16] .
There is no reason to suppose that all of the signalling pathways involved in either TSH or EGF actions are known. Indeed evidence exists that there may be more pathways awaiting discovery. One long-standing unexplained observation is that of Scott et al. [20] , who demonstrated a TSH-stimulated increase in de novo phosphatidylinositol (Ptdlns) synthesis in sheep and dog thyroid slices. In their study, the amount of Ptdlns synthesis was well in excess of that which would be required to resynthesize Ptdlns(4,5)P2 after PLC-mediated hydrolysis.
Metabolism of myo-inositol is central to cell signalling pathways, e.g. Ptdlns(4,5)P2 hydrolysis and receptor-mediated Ptdlns(3,4,5)P3 synthesis [21] . However, these pathways consume only a small fraction ( 5 as free myo-inositol, myo-inositol phosphates, Ptdlns and its phosphorylated derivatives, and inositol glycans (reviewed in [22, 23] ). In most cell types the intracellular myo-inositol concentration is regulated by the rate of myo-inositol transport [24] , and the transporter itself is regulated during differentiation [24, 25] . There is therefore potential for greater involvement of myo-inositol in signalling pathways than is presently appreciated. Using fully differentiated sheep and human thyroid cell cultures we have examined myo-inositol transport and its subsequent metabolism following treatment of the cells with TSH and EGF. These cells have advantages over studies with the rat thyroid cell line (FRTL5) or studies with primary dog thyroid cultures because they maintain the synthesis of thyroid hormones de novo [3] .
EXPERIMENTAL Cell culture
The isolation of sheep thyroid cells and their serum-free culture were as previously described [12] . Cells were used 7 to 10 days after isolation when a confluent monolayer had formed. Cultures were incubated in the absence of TSH or insulin for days (two medium changes) prior to the start of the experiment. Following these pre-incubation conditions TSH did not stimulate thyroid cell growth to any appreciable extent [2] . Aylesbury, U.K.) for 24 h. Total lipid extracts were isolated from the labelled cells and chemically degraded to yield samples of their fatty acid, glycerol and myo-inositol components, for all of which glucose is the only, or a major, biosynthetic precursor [26] . These moieties were separated by paper chromatography and their identity confirmed by ion-moderated partition chromatography on an Aminex HPX-87C carbohydrate column [26] .
myo-lnositol transport assay
For assays of myo-inositol transport, cultures were washed three times with 1 ml of incubation buffer (20 mM Hepes, 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 0.8 mM MgCl2, pH 7.4). Buffer (500,ul) containing 0. To allow for comparison of data the non-equilibrium data were also presented as pM averaged throughout the cell volume. It should be pointed out that these are not true concentrations. These procedures were necessary to correct for the large volume changes found upon treatment of the cells with the various hormones. myo-Inositol recycled to the medium was expressed as pmol/106 cells.
In all cases myo-inositol and its derivatives were extracted according to the method of Wregget and Irvine [27] . The lipid fraction was deacylated according to Clarke and Dawson [28] . The soluble and deacylated lipid fractions were separated by ionexchange chromatography on Sep-Pak QMA columns (Waters, Maidstone, U.K.) using a modification of the method of Maslanski and Busa [29] . Specifically, extracts were first brought to a pH greater than 9.0 by the addition of a few drops of 1 M NaOH. myo-Inositol was eluted in 15 ml of water, glycero- 
Arachidonic acid extractions
To determine the steady-state levels of arachidonic acid, cultures were equilibrium labelled (4 days) with 0.3 ,Ci/ml of [1-_4C] eicosatetraenoic acid (all from Sigma) made up to 1 mg/ml in ethyl acetate [31] . Location of radioactivity on the plates was determined by autoradiography and the appropriate spots were scraped into scintillation fluid and the radioactivity assayed. Table 3 show rapid cycling of myo-inositol between the intracellular and extracellular compartments with an influx rate exceeding the efflux rate by approximately 2-fold. The measured myo-inositol transport rate represents the accumulation of myo-inositol over and above the efflux rate, and as such is probably an underestimate of the true transport rate. The prolonged linearity of myo-inositol uptake is a characteristic of myo-inositol transport reported in a number of cell types (e.g. [36, 37] ). A plot of uptake rate versus substrate concentration showed that at higher substrate concentrations, transport was saturable ( Figure 3 ). Kinetic analysis of the data ( . These values closely match the kinetic parameters of myo-inositol transport from a wide variety of tissues and species [24, 36] . myo-Inositol transport in all cell types so far examined is sodium dependent [38] . Transport in sheep thyroid cells was assayed at a substrate concentration of 25 ,M in the presence or absence of sodium (140 mM) in the incubation buffer. Where sodium was omitted it was replaced with 140 mM CsCl. At 140 mM sodium the transport rate was 1.04 + 0.07 pmol/min per 106 cells (n = 3), while at 0 mM sodium the rate was 0.08 + 0.007 (n = 3; P < 0. Figure 4(a) 
Regulation of human thyroid myo-inositol transporter mRNA
To examine transcriptional regulation, total RNA extracted from human thyrocytes treated with TSH, EGF, or a combination, was analysed on a 1.0 % agarose gel in formaldehyde. A canine kidney Na+/myo-inositol co-transporter cDNA [34] was used to probe a blot of the gel ( Figure 6 ; representative of three separate blots TSH treatment ofthe thyrocytes produced a markedly different result. There was a 1.6-fold increase in the intracellular concentration of myo-inositol (P < 0.025) accompanied by significant rises in the concentrations of the soluble inositol phosphates, InsP2, InsP3, InsP4, InsP5 and InsP6 (Table 1 ).
The rise in intracellular myo-inositol concentration is in accordance with the rise in myo-inositol transport Vm.. seen in TSH-treated thyrocytes. The rise in the levels of InsP2, InsP. and InsP4 is consistent with a PtdInsP2 hydrolysis signalling event. Changes in intracellular concentrations of InsP5 and InsP6 have previously been noted in HL60 cells and normal blast cells undergoing differentiation [26, 42, 43] . DbcAMP was able to reproduce many of the effects of TSH as shown in Table 1 . The relative differences in the levels of InsP and InsP4 probably reflect increased flux down these pathways in dbcAMP-treated cells, in accordance with the greater increase in myo-inositol transport Vmax.
Treatment of thyrocytes with TSH plus EGF resulted in a significant rise in the levels of myo-inositol and all of its soluble derivatives and also in the levels ofPtdInsP. One major difference from that seen with either ligand alone was a noticeable rise in the levels of GroPIns from 21.14+4.30 ,M to 65.45+6.49,M (P < 0.01). This molecule reflects Ptdlns deacylation by PLA2 and a lysophospholipase [44] .
Effects of TSH, EGF and TSH plus EGF on myo-Inositol metabolism: pulse labelling study Maximal changes in the up-regulation of myo-inositol transport occurred after 24 h of treatment with ligand. The immediate fate of the transported myo-inositol at this time point was therefore determined by pulse labelling of thyrocytes after incubation for 24 h in the presence of agonist (Table 2) . No significant amounts of label were found in InsP3, InsP4, InsP5, or InsP)' under any of There was a modest (1.8-fold) increase in the incorporation of label into free myo-inositol in EGFtreated cells compared with control cells (P < 0.025). Otherwise there were no changes in the immediate destinations of myoinositol following EGF treatment when compared with controls. TSH treatment, however, resulted in a large increase in the incorporation of label into free myo-inositol (8.0-fold rise; P < 0.005), increases in incorporation into GroPIns, InsP and InsP2, and a 4. 1-fold increase in the incorporation ofmyo-inositol into Ptdlns (P < 0.01); the levels of the remaining lipids were unchanged. The increased incorporation of label into InsP and InsP2 again suggests the presence of a PLC-mediated signalling event. The increased incorporation of label into Ptdlns suggests that, in TSH-treated cells, the rate of Ptdlns synthesis is increased over control cells. Simultaneous treatment with TSH and EGF resulted in an increase in the incorporation of label into free myo-inositol (4.6-fold, P < 0.01), an increase in incorporation into GroPIns, and an increase in the incorporation of myo-inositol into Ptdlns (3.1-fold rise, P < 0.01). The increase in incorporation of label into GroPIns in TSH plus EGF-treated cells was more than additive.
The results obtained with pulse labelling of TSH-treated cells suggested that there was an increased synthesis of Ptdlns, yet the equilibrium labelling study showed no alteration in Ptdlns levels. One possible explanation of these results is that Ptdlns is rapidly turning over in TSH-treated cells. To examine this, pulse-chase labelling studies were performed.
Effects of TSH, EGF and TSH plus EGF on myo-inositol metabolism: pulse-chase labelling study Thyrocytes were pulse-labelled with [3H]myo-inositol for 15 min, followed by a chase with 50 ,M unlabelled myo-inositol for 15 min. Data are shown in Table 3 . After the 15 min chase the amount of label found in the free myo-inositol pool had significantly decreased from that found after the 15 min pulse, suggesting that myo-inositol entering this pool is quickly diverted elsewhere. The rate of flux of myo-inositol through this pool was similar in insulin-and EGF-treated cells, but was greatly increased in TSH-and TSH plus EGF-treated cells. Label from the myo-inositol pool appeared in GroPIns, InsP, InsP2, Ptdlns, PtdInsP, and PtdInsP2, but the majority of it (91-98 % in all cases) reappeared in the extracellular medium (Table 3) , suggesting that there was rapid cycling of myo-inositol between the intracellular and extracellular media. A similar finding was observed with GroPIns. This pool appeared to be rapidly turning over and there was a greater turnover rate in TSH-or TSH plus EGF-treated cells than there was for insulin-or EGF-treated cells. The incorporation of label into InsP and InsP2 respectively increased slightly after the 15 min chase or remained the same. Although levels of InsP and InsP2 in TSH-treated cells were increased, their rates of turnover were the same as in the control cells.
In all cases there was a significant increase in label in Ptdlns after the 15 min chase compared with the 15 min pulse, indicating that a proportion of the myo-inositol was used for PtdIns synthesis. The rate of synthesis of Ptdlns was higher in TSH-or TSH plus EGF-treated cells than in insulin-or EGF-treated cells. Increased amounts of label were found in PtdlnsP and unchanged amounts in PtdInsP2 in all cases, indicating the synthesis of these lipids from Ptdlns. In TSH-or TSH plus EGFtreated cells the increase in label found in Ptdlns at 30 min was half that found in EGF-or insulin-treated cells (1.7-fold increase versus 3.4-fold increase), suggesting that in these cells a proportion of the Ptdlns is metabolized rapidly and hence at 30 min the label has been diverted elsewhere.
Arachidonic acid metabolism The increased turnover of GroPIns (Tables 2 and 3) (Table 4) . To eliminate the possibility that arachidonic acid was being rapidly metabolized, indomethacin (15 ,uM), a cyclo-oxygenase inhibitor, was added for the final 2 h of culture. This also had no effect on the levels of arachidonic acid.
To determine whether turnover of arachidonic acid could explain these data, thyrocytes were treated with TSH (0. (Table 4) show that in the presence of TSH or TSH plus EGF there is increased turnover of (but not net production of) arachidonic acid. These results are in accord with the increased turnover of Ptdlns and GroPIns under these two conditions. The data suggest that the TSH-mediated increase in myo-inositol transport VM,: is associated with the PLA2-mediated turnover of Ptdlns and an increased turnover of arachidonic acid.
DISCUSSION
Previous studies have suggested that the rate of myo-inositol transport regulates the intracellular concentration ofmyo-inositol [24, 25] and that the rate of Ptdlns synthesis is dependent on the extracellular myo-inositol concentration [45] [46] [47] [48] . The data presented in this study confirm those observations and further demonstrate that the rate of Ptdlns synthesis is ultimately regulated by the rate of myo-inositol transport. The increase in GroPIns turnover associated with the increased Ptdlns turnover demonstrates that Ptdlns turnover occurs via hydrolysis and resynthesis of this lipid and not via the Ptdlns-inositol exchange reaction. The data suggest the presence of specific pools of myoinositol which are preferentially used for Ptdlns synthesis. Similar observations have been made in nerve and renal epithelium [47, 48] . The enzyme Ptdlns synthase (CDP-diacylglycerol-myoinositol-3-phosphatidyltransferase; EC 2.7.8.11; [49] ) regulates Ptdlns synthesis. This enzyme is found in the endoplasmic reticulum [50] , and a Ptdlns synthase has been described in the plasma membrane of a pituitary tumour cell line [51] . The plasma membrane enzyme has a considerably lower Km for myoinositol (67 ,uM) than the endoplasmic reticulum enzyme (1.5-4.5 mM; [50] ) which would allow it to regulate the turnover of plasma membrane Ptdlns in response to small (,uM) changes in the local myo-inositol concentration.
These observations provide an explanation for early results using dog and sheep thyroid slices in which increased Ptdlns turnover was noted following TSH stimulation [20] . They also link with previous observations that TSH can cause increases in the non-equilibrium levels of arachidonic acid [9, [52] [53] [54] . GroPIns is a product of the metabolism of Ptdlns by PLA2 followed by a lysophospholipase [44] . Ptdlns is enriched for arachidonic acid in the 2-position [55] ; therefore the production of arachidonic acid and GroPIns associated with Ptdlns turnover strongly suggests that TSH induced the PLA2-mediated turnover of Ptdlns. The effects are also found during the differentiation of HL60 cells towards monocytes, where there is an increase in the rate of myoinositol transport [25] and in the levels of arachidonic acid [56] .
An increase in the equilibrium levels of GroPIns has previously been postulated as either a marker for the transformation of cells with an oncogene [44] or as a product of the differentiation of certain cell types [43] . Elevation of the levels of GroPIns has been observed during HL60 cell differentiation towards neutrophils, and the differentiation of normal myeloid blast cells towards monocytes [26, 42, 43] . In the present study an increase in the equilibrium levels of GroPIns was not observed in TSH-stimulated (differentiating) cells, or in EGF-stimulated (growing) cells, but was observed in the presence of the two antagonistic stimuli. Elevations in the level of GroPIns may therefore be a marker ofcross-talk between several cellular signalling pathways.
The data demonstrate that in sheep and human thyrocyte cultures the rate of myo-inositol transport can be regulated during growth and differentiation. This phenomenon has previously been observed in myeloid cells differentiating towards monocytes or neutrophils [24, 25] , and in neuroblastoma cells [57] . However, this is the first report of regulation of myo-inositol transport during the growth and differentiation of non-transformed cells in response to physiological ligands. Regulation of the availability of myo-inositol may be a generalized feature of growth and differentiation. In human cells the up-regulation of myo-inositol transport was achieved via increased steady-state levels of the mRNA for the transporter. Together with the increased Vmax and the time course for the increase, these data suggest that up-regulation occurred via an increase in the number of transporters at the cell surface. Previous studies have also suggested that myo-inositol transport is regulated by altering the number of transporters at the cell surface [34, 58] .
The differences in the fate of the transported myo-inositol following TSH or EGF treatment illustrate the profound pheno-typic differences that these ligands induce. In the EGF-treated cells there are few significant changes in the metabolites of myoinositol compared with controls, and the increased uptake is probably related to the maintenance of the intracellular concentration of myo-inositol as the cells enlarge in preparation for division. Following TSH treatment, the increased cycling of myoinositol and PLA2-mediated turnover ofPtdlns suggest activation of further signalling pathways involved in cell differentiation. Generally, dbcAMP produced the same or similar results as TSH stimulation, suggesting that the TSH effects were mediated through cyclic AMP production. The peak increase in myoinositol transport occurred 24 h after TSH, and the same is also true for the turnover of Ptdlns and arachidonic acid. Membraneassociated signalling events usually occur within seconds of the original stimulus and are attenuated, at most, several hours afterwards [41] . The protracted time course of the TSH-induced Ptdlns turnover may be required for the temporal regulation of events many hours after the initiating stimulus. A recent report on FRTL5 cells shows that TSH induces an increase in diacylglycerol content and PKC activity 24 h post-addition [59] . Results described in this study demonstrate that there is more to the involvement of myo-inositol in cell signalling than the PLCmediated turnover of Ptdlns(4,5)P2, and that signalling events may be closely regulated hours and even days after the generation of the original second messenger.
